The effectiveness, safety and cost-effectiveness of cytisine versus varenicline for smoking cessation in an Australian population: a study protocol for a randomized controlled non-inferiority trial.

@article{Thomas2018TheES,
  title={The effectiveness, safety and cost-effectiveness of cytisine versus varenicline for smoking cessation in an Australian population: a study protocol for a randomized controlled non-inferiority trial.},
  author={Dennis Thomas and Michael Farrell and Hayden J McRobbie and Piotr Tutka and Dennis J. Petrie and Robert J West and Mohammad Siahpush and Coral E. Gartner and Natalie Walker and Colin Paul Mendelsohn and Wayne D. Hall and Christine Louise Paul and Nicholas A. Zwar and Stuart G. Ferguson and Veronica C Boland and Robyn Richmond and Christopher M Doran and Anthony P Shakeshaft and Richard P. Mattick and Ryan J Courtney},
  journal={Addiction},
  year={2018}
}
BACKGROUND AND AIMS Smoking cessation medications are effective, but often underutilized because of costs and side effects. Cytisine is a plant-based smoking cessation medication with more than 50 years of use in central and eastern Europe. While cytisine has been found to be well-tolerated and more effective than nicotine replacement therapy, direct comparisons with varenicline have not been conducted. This study evaluates the effectiveness, safety and cost-effectiveness of cytisine compared… 

Figures and Tables from this paper

The efficacy and safety of varenicline alone versus in combination with nicotine lozenges for smoking cessation among hospitalised smokers (VANISH): study protocol for a randomised, placebo-controlled trial
TLDR
The primary outcome is carbon monoxide validated prolonged abstinence from 2 weeks to 6 months after treatment initiation and secondary outcomes include self-reported and biochemically validated prolonged and point prevalence abstinence at 3, 6 and 12 months.
Cytisine for nicotine addiction treatment: A review of pharmacology, therapeutics and an update of clinical trial evidence for smoking cessation.
TLDR
The relative risks of abstinence in the efficacy analysis and RR of ARs, either reported by the authors or calculated from the reports, pooled to provide an updated meta-analysis of cytisine's efficacy and ARs for smoking cessation compared with placebo.
Current pharmacologic treatments for smoking cessation and new agents undergoing clinical trials
TLDR
A literature review revealed that bupropion may be appropriate for patients interested in reducing smoking who dislike, or who have failed, nicotine-replacement therapy (NRT).
Kobe University Repository : Kernel タイトル Tit le Current pharmacologic t reatments for smoking cessat ion and new agents undergoing clinical t rials
TLDR
A literature review revealed that bupropion may be appropriate for patients interested in reducing smoking who dislike, or who have failed, nicotine-replacement therapy (NRT).
Cytisine attenuates bone loss of ovariectomy mouse by preventing RANKL‐induced osteoclastogenesis
TLDR
The study indicated that Cytisine could suppress bone loss in OVX mouse through inhibited osteoclastogenesis and provide the evidence that cytisine may be a promising agent in the treatment of osteocline‐related diseases such as osteoporosis.

References

SHOWING 1-10 OF 37 REFERENCES
What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation.
TLDR
The expected value of sample information indicated that conducting a head-to-head trial of cytisine and varenicline was worthwhile, and that 1000 smokers per arm was an appropriate number to recruit.
Placebo-controlled trial of cytisine for smoking cessation.
TLDR
The lower price of cytisine as compared with that of other pharmacotherapies for smoking cessation may make it an affordable treatment to advance smoking cessation globally.
An uncontrolled trial of cytisine (Tabex) for smoking cessation
TLDR
The long-term abstinence rates were similar to those observed in smokers receiving nicotine replacement therapy, and full-scale randomised trials of cytisine (Tabex), conducted to the standards required by regulatory authorities, are warranted.
Efficacy of cytisine in helping smokers quit: systematic review and meta-analysis
TLDR
Cytisine is an effective treatment for smoking cessation with efficacy comparable to that of other currently licensed treatments, Given its low cost and potential for public health benefit, expedited licensing of cytisine forsmoking cessation is warranted.
Cytisine versus nicotine for smoking cessation.
TLDR
When combined with brief behavioral support, cytisine was found to be superior to nicotine-replacement therapy in helping smokers quit smoking, but it was associated with a higher frequency of self-reported adverse events.
Pharmacological interventions for smoking cessation: an overview and network meta-analysis.
TLDR
The outcome for benefit is continuous or prolonged abstinence at least six months from the start of treatment, and the outcome for harms is the incidence of serious adverse events associated with each of the treatments.
Cytisine for smoking cessation: a literature review and a meta-analysis.
  • J. Etter
  • Medicine
    Archives of internal medicine
  • 2006
TLDR
Cytisine may be effective for smoking cessation, and this fact remained largely unnoticed in the English-language literature.
Cytisine for the treatment of nicotine addiction: from a molecule to therapeutic efficacy.
TLDR
Since cytisine exhibits a desirable pharmacological profile which makes it an attractive smoking cessation drug, it should be advanced to randomized clinical trials, however, more detailed preclinical studies on its pharmacokinetics and safety profile are required.
...
...